Myth or Breakthrough in Oncology
Author : Dr. PD GUPTA
Former Director Grade Scientist, Centre for Cellular and Molecular Biology, Hyderabad, India
www.daylifenews.in
Cancer is one of the most dreadful diseases in the world, causing a significant increase in morbidity and mortality worldwide, regardless of modern medical developments. The cancer is characterized by the uncontrolled growth of aberrant cells, afflicting 19.3 million people and causing almost 10 million deaths globally as late as 2024
The concept of fasting as a cancer treatment has sparked significant debate and intrigue in both the medical community and the general public since I published this hypothesis in the Daccan Chronicle four decades back. Fasting, an ancient practice often associated with religious or cultural traditions, has gained renewed attention in recent years due to its potential therapeutic benefits in modern medicine, particularly oncology. The underlying hypothesis is that fasting alters the body’s metabolic state, creating conditions that may inhibit cancer growth and enhance the efficacy of conventional treatments. Proponents of fasting argue that it can induce autophagy, a process where the body clears damaged cells and regenerates healthier ones, and that it may make cancer cells more vulnerable to treatment by depriving them of glucose and other essential nutrients needed for rapid proliferation. Cancer cells are voracious eaters and they die very soon if they do not get food. In addition, fasting is believed to trigger a stress-resistant state in normal cells, offering protection against the toxic side effects of chemotherapy and radiotherapy, while selectively targeting cancer cells, which are less adaptable to nutrient scarcity. These concepts are grounded in research that shows how cancer cells exhibit altered metabolism, often referred to as the “Warburg effect,” where they preferentially rely on glycolysis for energy even in the presence of oxygen. By restricting glucose availability through fasting, it is thought that the growth of cancer cells may be slowed or halted. Despite the intriguing scientific basis, the idea of using fasting as a primary treatment for cancer remains controversial. Much of the current evidence supporting fasting’s anti-cancer effects comes from animal studies and in vitro experiments, with limited large-scale human trials to corroborate these findings. In rodent models, fasting has shown promise in reducing tumor growth, improving the effectiveness of chemotherapy, and enhancing overall survival. However, translating these results to humans is complex due to differences in physiology, tumor types, and individual patient health statuses. While some small clinical trials have suggested that short-term fasting or fasting-mimicking diets may improve patients’ tolerance to chemotherapy and reduce side effects, the long-term safety and efficacy of such interventions in treating cancer remain uncertain. Furthermore, the type of fasting regimen, whether intermittent fasting, prolonged fasting, or calorie restriction adds another layer of complexity to the discussion, as different cancers and patients may respond differently to various fasting protocols. Another concern with fasting as a cancer treatment is its potential for malnutrition, particularly in cancer patients who are already at risk of weight loss and muscle wasting due to their disease. Cancer cachexia, a syndrome characterized by severe muscle loss and fat depletion, affects many cancer patients and can significantly impact treatment outcomes and quality of life
. Fasting, if not carefully managed, could exacerbate these issues, leading to weakened immune function, reduced tolerance to treatment, and overall poorer prognosis. For these reasons, many oncologists are cautious about recommending fasting as a therapeutic strategy, particularly outside of controlled clinical settings. While the idea of fasting as a cancer treatment is compelling and has generated considerable interest, it remains largely experimental at this stage. The potential benefits of fasting, especially as an adjunct to conventional therapies, are worthy of further exploration, but there is insufficient evidence to support its use as a standalone treatment. More robust clinical trials are needed to determine the efficacy, safety, and optimal conditions under which fasting might be beneficial in cancer care.
Despite the intriguing scientific basis, the idea of using fasting as a primary treatment for cancer remains controversial. Much of the current evidence supporting fasting’s anti-cancer effects comes from animal studies and in vitro experiments, with limited large-scale human trials to corroborate these findings. In rodent models, fasting has shown promise in reducing tumor growth, improving the effectiveness of chemotherapy, and enhancing overall survival. However, translating these results to humans is complex due to differences in physiology, tumor types, and individual patient health statuses. While some small clinical trials have suggested that short-term fasting or fasting-mimicking diets may improve patients’ tolerance to chemotherapy and reduce side effects, the long-term safety and efficacy of such intervention. (The author has his own study and views)